ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg
ISU304-001/CB2679d
Phase 1 mab completed
Quick answer
ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg for Hemophilia B is a Phase 1 program (mab) at CATALYST PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- CATALYST PHARMACEUTICALS, INC.
- Indication
- Hemophilia B
- Phase
- Phase 1
- Modality
- mab
- Status
- completed